ÂÜÀòÂÒÂ×

Jay S. Stout, PhD is the Chief Technology Officer at Immunovant. From 2020 until April 2023, he was an independent consultant supporting the scale up and validation of late stage products in Immunology and Cell and Gene Therapy. From June 2018 until January 2021, he led the Technical Operations at Immunomedics (Gilead) leading to the approval of an Antibody Drug Conjugate for Oncology. Prior to that Dr. Stout has held various senior leadership roles in Technical Operation at Versartis (Aravive), San Bio, Merck, Amgen, Pfizer, and BioNebraska (Restoragen). He has a proven track record of Biologic approvals for Monoclonal Antibodies, Antibody Drug Conjugates, and Cell and Gene Therapies.

Dr. Stout received a BS and MS in Chemistry from the University of Iowa and a PhD in Chemistry and Biochemistry from the University of Nebraska-Lincoln. Dr. Stout has served on the Amgen Center for BioProcessing Advisory Board at the Keck Graduate Institute for more than 10 years and was the Chair of the Advisory Board from 2021-2023.